Yano, S., Yamada, T., Takeuchi, S., Tachibana, K., Minami, Y., Yatabe, Y., Mitsudomi, T., Tanaka, H., Kimura, T., Kudoh, S., Nokihara, H., Ohe, Y., Yokota, J., Uramoto, H., Yasumoto, K., Kiura, K., Higashiyama, M., Oda, M., Saito, H., Yoshida, J., Kondoh, K. and Noguchi, M. (2011) Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. Journal of Thoracic Oncology, 6, 2011-2017.
https://doi.org/10.1097/JTO.0b013e31823ab0dd

has been cited by the following article:

• TITLE: Dual Epidermal Growth Factor Inhibition and Multi Targeted Epigenetic Therapy (MTET)

  AUTHORS: Mohammad Nezami, Steve Hager

  KEYWORDS: Epidermal Growth Factor, Lung Cancer, Epigenetic Therapies, Targeted Therapies, Afatinib

  JOURNAL NAME: Journal of Cancer Therapy, Vol.9 No.11, November 14, 2018

  ABSTRACT: Since the discovery of tyrosine kinase inhibitors in treatment of lung cancer harboring such actionable targets, many lives have been prolonged. To the same extent, same group of patients have failed to benefit from this category of drugs, in long run, either initially or during the course of treatments, simply due to either known or unknown mechanism of resistance which occurs very often in the first few months after initiation of therapy. The resistance is 100 percent expected, and no patient is reported to be a waiver of such pattern. With best practices of oncology, the average duration of response is expected to be below 12 months [1]. About half of the resistance is caused by mutation at T790M in EGFR target, which can be revealed by liquid biopsy [1] [2]. The most recent studies have revealed the significant role of epigenome in controlling this complicated resistance pattern. We have learned that Histone deacetylation, as opposed to promoter methylation, may contribute to the epigenetic silencing and to EGFR TKI resistance in NSCLC [3] [4]. Here we present a case study with a model of combinational therapy that targets the EGFR molecule, (by small molecule inhibitor, Afatanib) with simultaneous epigenetic modification of the target, (by application of multitargeted epigenetic therapy (MTET) with significantly improved clinical results. We propose further trials are needed to support such hypothesis, which if proved, could significantly shift the current practices in management of this set of cases in lung adenocarcinomas.